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MaOBJECTIVES The aim of this study was to evaluate long-term outcomes in patients with atrial ﬁbrillation undergoing
percutaneous left atrial appendage (LAA) closure with the Watchman device.
BACKGROUND Atrial ﬁbrillation is one of the most common arrhythmias and is associated with a high risk for
cardioembolic ischemic events, most notably stroke. Percutaneous LAA closure is an alternative to oral anticoagulation,
because most thrombi originate from the LAA.
METHODS All consecutive patients with minimum CHADS2 or CHA2DS2-VASc scores of 1 who underwent LAA closure
with the Watchman device between June 2006 and August 2010 were eligible. Follow-up examinations were performed
after 45 days to 3 months, 6 months, and 1 year and thereafter annually. Afterward, alternating ofﬁce visits and
telephone follow-up were performed every 6 months.
RESULTS A total of 102 patients were included. The mean age was 71.6  8.8 years, and 37.3% were women. The mean
CHADS2 and CHA2DS2-VASc scores were 2.7  1.3 and 4.3  1.7, respectively. Procedural success was achieved in 96.1%
of patients. During a mean follow-up period of 3.0  1.6 years, the annual rates of transient ischemic attack, stroke,
intracranial hemorrhage, and death were 0.7%, 0.7%, 1.1%, and 3.5%, respectively.
CONCLUSIONS LAA closure with the Watchman device is safe and feasible for stroke protection in patients with
atrial ﬁbrillation. Low ischemic events rates demonstrate its effectiveness during long-term follow-up.
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
LAA = left atrial appendage
TEE = transesophageal
echocardiography
TIA = transient ischemic attack
VKA = vitamin K antagonis
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1916Marlborough, Massachusetts) is an alterna-
tive to medical therapy in these patients
because pathological studies have demon-
strated that in patients with AF, at least
90% of all thrombi originate in the LAA (4).SEE PAGE 1922The PROTECT-AF (Watchman Left Atrial
Appendage System for Embolic Protectionin Patients with Atrial Fibrillation) trial recently
demonstrated noninferiority of device closure with
the Watchman device in comparison with conven-
tional anticoagulation with VKAs (6). Subsequently,
percutaneous LAA closure was incorporated into
current European guidelines, which describe LAA
closure to be reasonable in patients with long-term
contraindications to oral anticoagulation (7). Howev-
er, data beyond the PROTECT-AF trial, speciﬁcally
regarding long-term results, are pending. In this
present analysis, we aimed to evaluate the long-term
outcomes of patients with AF treated with the
Watchman device on the basis of the real-world
setting of a single center.
METHODS
This prospective single-center analysis included all
consecutive patients who underwent implantation
of the second-generation Watchman device between
June 2006 and August 2010. All patients received and
signed an informed consent document at least 24 h
before the procedure. All examinations were per-
formed in accordance with the Declaration of Helsinki
(revisions of 2008 and 2013).
PATIENTS. Patients with nonvalvular AF and CHADS2
or CHA2DS2-VASc scores of at least 1 were included.
Echocardiographic criteria for implantation were an
ejection fraction $30% and the absence of severe
mitral insufﬁciency, mitral stenosis, or thrombus
formation in left atrium and/or in the LAA. Patients
with large patent foramen ovales, deﬁned as patent
foramen ovales with atrial septal aneurysms (total
excursion >15 mm or length $15 mm) or large shunts
(substantial passage of bubbles within 3 beats) were
excluded as well. Only patients whose LAA lengths
were greater than their ostial diameters were
included. Patients with intolerance to aspirin were
excluded.
DEVICE AND PROCEDURE. The Watchman LAA
closure device has a self-expanding nitinol cage with
a permeable polyester fabric on the surface and ﬁxa-
tion barbs surrounding the perimeter. The device is
delivered through a 12-F catheter requiring femoral
tvenous access and transseptal puncture with the
insertion of a 14-F transseptal sheath. Five different
sizes from 21 to 33 mm in 3-mm increments are
available. A device slightly (8% to 20%) larger than
the maximal LAA ostial diameter as measured by
angiography and transesophageal echocardiography
(TEE) was chosen. Compression grade was calculated
(device diameter after implantation/diameter before
implantation) to ensure safe position. The optimal
compression grade was considered to range between
80% and 92%. Further procedural details have been
published elsewhere (6).
After the procedure, patients were hospitalized
for at least 1 day. Transthoracic echocardiography
and electrocardiographic monitoring were per-
formed to exclude pericardial effusion and potential
arrhythmias.
MEDICATIONS. In the absence of contraindications
to anticoagulation, VKAs were administered for 45
days with heparin bridging until the international
normalized ratio was in a therapeutic range (2.0 to
3.0). Aspirin therapy (100 mg/day) was started on the
day before implantation and continued lifelong. Clo-
pidogrel was started at the 45-day follow-up visit and
was continued until 6-month follow-up. Patients not
eligible for anticoagulation (n ¼ 25) were treated with
lifelong aspirin (100 mg/day), which started the day
before implantation, and clopidogrel (75 mg/day)
starting from the day of implantation until comple-
tion of the 6-month follow-up. Endocarditis prophy-
laxis was recommended up to 6 months after
implantation.
FOLLOW-UP. Follow-up examinations, including in-
ternational normalized ratio monitoring (for anti-
coagulated patients) and electrocardiography, were
performed between 45 days and 3 months (for non-
anticoagulated patients) after implantation. At the
same time, peridevice ﬂow, device stability, and
positioning were evaluated by TEE. Electrocardiog-
raphy and TEE were repeated at the 6-month and
1-year follow-up visits. Follow-up via telephone was
performed at month 9. After 1 year, another ofﬁce
follow-up visit was scheduled, including TEE, elec-
trocardiography, and physical examination. After-
ward, follow-up via telephone and ofﬁce follow-up
visits, including electrocardiography and physical
examination, were performed alternately every 6
months.
STATISTICAL ANALYSIS. Data are presented as fre-
quencies and percentages for categorical variables
and mean  SD for continuous variables. For compar-
ison of categorical variables, the Fisher exact test or
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1917chi-square test was applied, whereas for continuous
variables, the Mann-Whitney U test was used. These
tests were calculated 2-tailed, and p values<0.05 were
considered to indicate statistical signiﬁcant. Further-
more, Kaplan-Meier analyses were performed. Statis-
tical analysis was performed with Prism 6 (GraphPad
Software, Inc., La Jolla, California).RESULTS
BASELINE EVALUATION. One hundred two patients
were eligible for this evaluation. The mean age was
71.6  8.8 years, and 37.3% (38 of 102) were women.
The mean CHADS2, CHA2DS2-VASc, and HAS-BLED
scores were 2.7  1.3, 4.3  1.7, and 2.9  1.2,
respectively. TEE of the LAA revealed a mean ostial
diameter of 22.2  3.5 mm and a mean length of 32.4 
6.8 mm. The LAA was multilobed in 54.9% of pa-
tients. Further baseline characteristics are presented
in Table 1.
PROCEDURAL RESULTS. Successful implantation of
the device was achieved in 96.1% of patients (98 of
102). In 4 patients, implantation was not possible
because of unfavorable anatomic features. For
adequate positioning, partial recapture were required
in 26.5% of patients (27 of 102). Full recapture and
subsequent replacement of the device because of
inappropriate device size were needed in 31.4% (32 of
102). The mean compression grade after successful
deployment was 84.9  6.4%. Post-implantation TEE
and ﬂuoroscopic imaging demonstrated successfulTABLE 1 Baseline Characteristics (n ¼ 102)
Age (yrs) 71.6  8.8
CHADS2 score 2.7  1.3







Congestive heart failure 36.3% (37)
Hypertension 91.2% (93)
Age 65–74 yrs 43.1% (44)
Age $75 yrs 39.2% (40)
Diabetes 27.5% (28)
History of stroke 17.6% (18)
History of TIA 22.5% (23)
Vascular disease 45.1% (46)
Women 37.3% (38)
Values are mean  SD or % (n).
TIA ¼ transient ischemic attack.closure of the LAA in 97 of 98 patients. In 1 patient,
the device was deployed in 1 lobe of a multilobed
appendage and could not be recaptured or reposi-
tioned adequately. Because of the uncovered lobe,
the patient was advised to stay on VKA therapy. The
mean procedure time was 54.5  22.0 min. The mean
total ﬂuoroscopy time was 8.8  3.8 min. The mean
amount of contrast agent was 146.5  52.5 ml. Dual-
antiplatelet therapy was administered for 6 months
in 41.8% of patients (41 of 98). All others (58.2%
[57 of 98]) received VKAs for 45 days and dual-
antiplatelet therapy afterward until completion of
6-month follow-up.
Procedure-related adverse events occurred in
8.8% of patients (9 of 102). Three patients had
hemodynamically relevant pericardial effusions
and underwent successful pericardiocentesis. Four
patients had evidence of hemodynamically nonrel-
evant pericardial effusions, which were treated
conservatively. One patient had an allergic exan-
thema, and 1 patient had minor post-procedural
femoral bleeding.
Comparison of procedural parameters and
procedure-related complications did not show any
statistically relevant differences between the ﬁrst 51
and second 51 consecutive patients. Further results
are presented in Table 2.
FOLLOW-UP OUTCOMES. The mean follow-up
duration for 96 patients (after inclusion, 2 patients
refused to undergo follow-up visits at our center)
was 3.0  1.6 years, with a maximum of 5 years and
a total of 276.6 documented patient-years. During
this period, there was no evidence of relevant re-
sidual peridevice leakage $5 mm, except in the pa-
tient with the uncovered lobe mentioned previously.
In 2 patients, thrombus formation was detected on
the device 3 and 6 months after the procedure,
respectively. Both patients were asymptomatic andTABLE 2 Comparison of Procedural Findings Between the First and Second Consecutive








p Value (First vs
Second Cohort)
Mean procedure time (min) 54.5  22.0 53.3  24.1 55.6  19.8 0.2920
Fluoroscopy time (min) 8.8  3.8 9.1  3.7 8.6  3.9 0.4293
Amount of contrast agent (ml) 146.5  52.5 143.9  49.4 149.1  55.8 0.4911
Need for full recapture 31.4% (32) 25.5% (13) 37.3% (19) 0.2004
Mean number of devices
deployed per procedures
1.3  0.6 1.2  0.6 1.4  0.6 0.1464
Procedure failure 3.9% (4) 3.9% (2) 3.9% (2) 1.0000
Procedure-related complications 8.8% (9) 11.8% (6) 5.9% (3) 0.4874
Values are mean  SD or % (n).
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At the next follow-up visits, the thrombi were
dissolved.
Two patients had ischemic strokes more than
12 months after implantation. Two further patients
had transient ischemic attacks (TIAs), 1 patient
1 month and the other patient more than 12 months
after the procedure. Three patients had evidence of
intracranial bleeding, 1 patient while on VKA and
aspirin, the second patient while on aspirin and clo-
pidogrel therapy, and the third patient while on
aspirin therapy only. The latter patient died 26months
after the procedure.
The rate of cerebral ischemia (including TIA and
stroke) during follow-up was 1.4 per year, and the
combined rate of cerebral ischemia and intracranial
bleeding was 2.5 per year. Survival free of stroke or
TIA of any origin was 92.7% (89 of 96).
Patients on aspirin and VKAs for 45 days and
afterward on aspirin and clopidogrel until 6 months
after the procedure (n ¼ 55) did not show any evi-
dence of thrombi on the LAA occluder and had no
ischemic events during this period. In those patients
who received aspirin and clopidogrel for 6 months
(n ¼ 41), thrombi on the LAA occluder occurred in 2
cases, and 1 ischemic event was noted during this
time (0 of 55 vs. 2 of 41).
Severe bleeding complications requiring hospi-
talization occurred in 6 patients, and the annual
rate was 2.1%. Besides the previously mentioned
intracranial hemorrhages, 1 patient was admitted to
the hospital 1 month after the procedure (while on
aspirin and VKA) because of a TIA, and this patient
experienced severe pharyngeal bleeding during TEE
and subsequently died. Another patient died of se-
vere gastrointestinal bleeding more than 12 months
after the procedure while on aspirin. One patientTABLE 3 Follow-Up Outcomes
Follow-up time 3.0  1.6
Total patient-yrs 276.6
Post-procedural DAPT for 6 months 41.8% (41/98)
Post-procedural VKA and aspirin for 45 days 58.2% (57/98)





Total major bleeding complications 2.1%
Deaths 3.5%
Values are mean  SD, % (n/N), or % per year.
DAPT ¼ dual-antiplatelet therapy; TIA ¼ transient ischemic attack; VKA ¼
vitamin K antagonist.was hospitalized because of melena more than
2 years after the implantation. At that time, the
patient was on aspirin and clopidogrel because of
coronary artery disease.
A total of 7 further patients died during follow-up,
resulting in an annual rate of 3.5%. One patient
committed suicide, 2 patients died of cancer, and 1
patient died of pulmonary embolism. One patient
died of global respiratory insufﬁciency related to
severe chronic obstructive pulmonary disease and
pneumonia, and in 2 patients the causes of death
remained unknown. An overview of long-term
outcome is presented in Table 3 and Figure 1.
DISCUSSION
The presented results show that percutaneous
LAA closure with the Watchman device can be per-
formed with high procedural success and a low rate
of severe procedure-related adverse events. The
evaluation of procedural characteristics in the ﬁrst
and second consecutive halves of the cohort did
not reveal clear evidence of a learning curve, as
no statistically relevant difference were detected.
Nevertheless, a trend toward fewer procedure-related
complications in the second group was noted
(11.8% vs. 5.9%, p ¼ 0.4874), which was not statisti-
cally relevant, most probably because of the small
number of patients. In addition, a learning curve with
the Watchman device was observed in a large study
of 1,002 patients, with a signiﬁcant increase of proce-
dural success and a reduction of procedure-related
adverse events over time (8).
At present, there is a lack of long-term data, as
most of the existing data were derived from the
PROTECT-AF trial. To the best of our knowledge, this
study had the longest follow-up duration besides
PROTECT-AF so far. Sick et al. (9) were the ﬁrst to
describe data with a follow-up period of approxi-
mately 2 years in 66 patients treated with the
Watchman device, and only 2 TIAs occurred. Another
investigation of 58 patients found 1 stroke in 25
months of follow-up (10). Moreover, long-term data
with the former percutaneous LAA transcatheter
occlusion device (ev3 Inc., Plymouth, Minnesota)
exist. Investigations of the percutaneous LAA trans-
catheter occlusion device with 58 and 73 patients
and follow-up periods of 4 and 2 years, respectively,
demonstrated annual stroke rates of 3.8% and 0%,
respectively (11,12). In addition, a study of 134 patients
treated with the Amplatzer Cardiac Plug, with a mean
follow-up duration of almost 2 years (680 days),
was performed, and an annual stroke rate of 0.8%
was observed (13). However, there are substantial
FIGURE 1 Kaplan-Meier Curves of Incidence of Endpoints
Stroke/ TIA All stroke
All-cause mortalityAll-cause mortality/ all stroke
Time since implantation (months) Time since implantation (months)
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Incidence of stroke and transient ischemic attack (TIA) (A), hemorrhagic and ischemic stroke (B), all-cause mortality and all-cause stroke (C),
and all-cause mortality (D) for all patients with successful Watchman implantation are illustrated over time.
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1919differences in the design of the occluders and in
the post-procedural medications. Furthermore, the
percutaneous LAA transcatheter occlusion device is
no longer available.
Two randomized controlled trials compared oral
anticoagulation with VKAs and LAA closure with
the Watchman device, and noninferiority in terms
of stroke prevention was demonstrated in both
(6,14). In the previously mentioned PROTECT-AF
trial, 463 patients were treated with the Watchman
device. The observed stroke rates consistently
decreased over time: 2.2%, 1.9%, and 1.4% per
100 patient-years after 18 months, 2.3 years, and
3.8 years, respectively (6,15,16). According to the
mean CHADS2 score of 2.7 in this population, the
estimated annual stroke risk for patients not takingoral anticoagulation is between 2.5% and 5.3% and
for patients on VKAs is between 1.3% and 2.2%,
respectively (17). These results are consistent with
our ﬁndings: in our investigation, the observed
annual rate of ischemic stroke was 0.7%, and the
combined rate for ischemic stroke and TIA was 1.4%.
Even if both deaths of unknown cause were consid-
ered cerebral ischemic cardioembolic events, the
yearly rate would have been 2.1%. Taking the event
of cerebral bleeding into account as well, the calcu-
lated yearly rate of cerebral events of any cause
would have been 3.2%. These results are substan-
tially lower than predicted for patients without
anticoagulation. Additionally the rate of actually
observed ischemic events is even lower than
expected for patients under VKA therapy.
PERSPECTIVES
WHAT IS KNOWN? Percutaneous LAA closure of-
fers a reasonable alternative to oral anticoagulation
because its safety and efﬁciency have been demon-
strated in a randomized controlled trial. However,
long-term data are lacking.
WHAT IS NEW? The follow-up up to 5 years in the
present cohort reveals annualized rates of TIA or
stroke of 1.4% and of major bleeding complications of
2.1% per year and suggests sufﬁcient long-term
stroke protection with a reasonable safety proﬁle.
WHAT IS NEXT? Further long-term data, especially
those derived from randomized controlled trials, will
be needed to support these ﬁndings, and additional
studies regarding optimal post-procedural anticoag-
ulant and antiplatelet therapy will be required as well.
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1920Certainly it must be noted that the post-procedural
anticoagulant therapy regime of the analyzed popu-
lation was inconsistent in contrast to both random-
ized studies. Nevertheless, because of this fact, some
secondary ﬁndings were detected. During the ﬁrst 6
months, no relevant differences between both groups
were found with regard to the occurrence of thrombi
on the LAA occluder, ischemic events, and cerebral
bleeding. The ASAP (ASA Plavix Feasibility StudyWith
Watchman Left Atrial Appendage Closure Technology)
trial evaluated 150 patients with a mean CHA2DS2-
VASc score of 4.4 treated with the Watchman
and contraindications to VKAs in a nonrandomized
fashion, who received dual-antiplatelet therapy for
6 months, followed by aspirin monotherapy. During
14.4 months of follow-up, the annual stroke rate was
1.7%, and 0.6% experienced cerebral hemorrhages
per year (18). These results are comparable with
our ﬁndings, because the annual rates of cranial
bleeding and ischemic events (TIA and stroke) were
0.5% and 1.1% per year in patients treated with
dual-antiplatelet therapy only.
According to the mean HAS-BLED score of 2.9  1.2,
our patient population was at a high bleeding risk
according to current European Society of Cardiology
guidelines. The theoretical annual bleeding rate un-
der anticoagulation was 3.74% (7,19). The actual
observed major bleeding rate was 2.1% per year,
which was substantially lower than expected. This
observation may be affected by patient selection and
by discontinuation of oral anticoagulation or dual-
antiplatelet therapy. Nevertheless, LAA closure
seems to be reasonable to prevent severe bleeding
complications, especially in high-risk patients. How-
ever, post-procedural antiplatelet and anticoagulant
medications are heterogeneous within different
studies. The optimal medication and duration have
not been determined thus far. Thus, the impact of
different post-procedural regimes on long-term
outcome is not clear and may need further evalua-
tion in a randomized fashion. New anticoagulant
agents and shorter dual-antiplatelet therapy dura-
tions should be considered, as data on safe LAA
closure with minimal antiplatelet therapy are sparse,
and several patients show contraindications to
contemporary anticoagulant therapy (20).
STUDY LIMITATIONS. Some limitations apply to our
investigation. Different post-procedural anticoagu-
lant and antiplatelet regimes were used within the
ﬁrst 45 days after implantation. Their impact on long-
term results has not been evaluated so far and may be
not interpretable in this particular cohort, because ofits relatively small sample size. Furthermore, 2 pa-
tients withdrew consent and 2 patients died of un-
known causes. In these patients, cardioembolic
events and bleeding complications could not be ruled
out with full certainty. Although data were entered in
a prospective, non-randomized manner, the present
study is subject to the characteristic shortcomings of
a single-center registry. Nevertheless, its clinical
practice-based approach over a period of up to 5 years
is also 1 of the main values of this present study. The
all-comer population of patients undergoing LAA
closure allows long-term analysis of those who, for
various reasons, would have been excluded by
contemporary study protocols.
CONCLUSIONS
Our ﬁndings suggest that low procedural complica-
tion rates with the Watchman device may result in a
more pronounced beneﬁt of percutaneous LAA oc-
clusion than previously expected. Long-term data
from our study conﬁrm the safety and efﬁcacy of LAA
occlusion with the Watchman device for stroke pro-
tection, irrespective of the post-procedural anticoag-
ulant regime. Thus, LAA occlusion represents a
reasonable alternative to oral anticoagulation.
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